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Abstract
  
 
Objective: To evaluate the effects on mood of a substantial
 and prolonged 
reduction in total cholesterol concentration.
  
Design: Randomised placebo controlled comparison of patients
 who had been 
allocated to receive simvastatin 20 mg or 40 mg
 daily versus those allocated 
matching placebo in a ratio of
 2:1. Follow up at an average of 152 weeks after 
randomisation.
  
Subjects: Men and women aged between 40 and 75 years at entry
 with blood total 
cholesterol of 3.5 mmol/l or greater, who were
 considered to be at higher than 
average risk of coronary heart
 disease based on medical history.
  
Main outcome measures: The shortened profile of mood states
 questionnaire, 
reported use of psychotropic medication, and
 symptoms possibly related to mood.
  
Results: Simvastatin reduced total cholesterol by 1.9 mmol/l
 (26.7%) at the time 
of follow up. Among all 621 patients randomised
 to simvastatin (414 patients) or 
placebo (207 patients) there
 were no significant differences in the use of 
psychotropic medication
 or in reports of symptoms possibly related to mood. Of 
these
 patients, 491 (334 simvastatin, 157 placebo) completed the mood
 
questionnaire, and there were no significant differences between
 the treatment 
groups in total or subscale scores, even when
 patients with low baseline 
cholesterol concentrations or elderly
 subjects were considered separately.
  
Conclusion: These results do not support the hypothesis that
 treatment to lower 
cholesterol concentration causes mood disturbance.
  
 
 
Key messages 
•  A randomised placebo controlled trial of simvas- tatin (a drug that 
lowers cholesterol concentration substantially) showed no associated 
   mood distur- bance over a period of nearly three years in subjects 
with cardiovascular disease and no pre-existing psychiatric 
conditions 
•  No effects on mood were seen in individuals with low baseline 
cholesterol concentrations or in older individuals, and there were no 
differences in use of psychotropic drugs between the treatment 
groups 
•  These results give little support to the idea that reducing cholesterol 
concentration has adverse effects on mood 
Introduction
  
The apparent association between low
1 
2 
3 or lowered
4 plasma
 cholesterol 
concentrations and death from causes other than
 illness, particularly suicide, has 
prompted suggestions that
 low cholesterol concentration might cause mood 
disturbances.
5 In cross sectional studies associations between cholesterol
 
concentration and depressive symptoms have been inconsistent,
 with a higher 
prevalence of depression among the group with
 the lowest concentrations in some 
studies or in selected subgroups
6 7 
8 but not in others.
9 
10 
11 An alternative 
explanation for
 these associations is that poor or declining health might cause
 both 
a fall in blood cholesterol concentrations and an increase
 in depressive illness.
8 
12  
Evidence for the effects of lowering blood cholesterol on mood
 states and 
behaviours is limited. Studies in monkeys have shown
 low fat diets to be 
associated with aggressive behaviour.
13 One intervention study in humans 
evaluated the effects on mood
 of dietary treatment to lower cholesterol 
concentration and
 found no adverse effects, but the study lacked any control group
 
and the reduction in cholesterol was minimal.
14  
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA)
 reductase, a 
rate limiting enzyme in hepatic cholesterol synthesis,
 produce large, sustained 
reductions in cholesterol concentrations
 and are now widely used to treat 
hypercholesterolaemia.
15 Recently,
 a randomised placebo controlled trial of one of 
these agents,
 lovastatin, showed no effect on patients' ratings of subjective
 health 
or emotional wellbeing during one year's treatment of
 older adults with mild to 
moderate hypercholesterolaemia.
16 The present study concerns data on mood 
states and use of psychotropic
 drugs after about three years of treatment in the 
Oxford cholesterol
 study,
17 a randomised placebo controlled study of simvastatin,
 
another HMG CoA reductase inhibitor.
  
Methods
  
A detailed description of the design and three year follow up
 results of the study is 
reported elsewhere,
17 and details relevant
 only to the present study are presented 
here. The Central Oxford
 Research Ethics Committee approved the study protocol.
 
ELIGIBILITY AND ROUTINE DATA COLLECTION
  The participants in the study were 621 men and women aged between
 40 and 75 
years with blood total cholesterol concentration of
 3.5 mmol/l or greater, who 
were considered to be at higher than
 average risk of coronary heart disease 
(because of a history
 of myocardial infarction, angina pectoris, stroke, transient
 
ischaemic attack, peripheral vascular disease, treated diabetes
 mellitus, or 
hypertension) and for whom there were neither contraindications
 to, nor specific 
indications for, HMG CoA reductase inhibitors.
 Subjects were also excluded if 
there was evidence of alcohol
 or drug misuse or of psychiatric disability which 
might limit
 compliance. At the initial screening visit to the clinic for
 the study, 
patients completed a detailed questionnaire about
 their medical and treatment 
history, blood pressure was measured,
 and a non-fasting blood sample was taken 
for laboratory analysis.
 All screened subjects were given dietary information 
similar
 to that contained in the American Heart Association step 1 diet
 guidelines. 
After an eight week, single blinded placebo run
 in period, subjects who were 
compliant with medication and were
 willing to continue with treatment for at least 
five years were
 evenly randomised to take 40 mg simvastatin daily, 20 mg 
simvastatin,
 or placebo. Blinded follow up of mortality and major morbidity
 still 
continues.
  
After the randomisation clinic visit (study week 0) all patients
 were to be seen at 
eight weeks, then at 12 weekly intervals
 for about one year, and then at 24 weekly 
intervals. At each
 follow up visit, patients were asked whether they had 
experienced
 any of a prespecified list of symptoms (including insomnia or
 
fatigue). Any other symptoms volunteered (such as depression
 or irritability) were 
recorded. All hospital admissions, possible
 adverse drug reactions, and reasons for 
non-compliance with
 treatment were recorded. Additionally, at annual visits, 
details
 of other medication (including psychotropic drugs) being taken
 at the time 
of follow up were recorded. Non-fasting blood samples
 were taken for laboratory 
analysis from all patients attending
 follow up visits. Patients were encouraged to 
attend their scheduled
 follow up visits even if they had stopped study treatment. 
Those
 who declined further clinic follow up had their study treatment
 stopped but 
were still to be followed at the scheduled time
 by telephone or through their 
general practitioner.
  
PROFILE OF MOOD STATE QUESTIONNAIRE
  
Between April and October 1992, at an average of about 152 weeks
 after 
randomisation, mood was assessed with a shortened version
 of the profile of mood 
state questionnaire. This abbreviated
 version was quicker and simpler to complete 
than the full questionnaire
 and was sent to all surviving patients in the study who 
were
 attending the clinic or being followed up by telephone for their
 completion 
and return. The questionnaire has six subscales:
 tension/anxiety, anger/hostility, 
fatigue/inertia, confusion/bewilderment,
 depression/dejection, and vigour/activity. 
The six items from
 each subscale that loaded highest on each factor in the factor
 
analysis
18 were used in the shortened mood scale.
19 This reduces
 the burden on the 
patients without seriously compromising the
 validity of the scale.
20 Patients were 
given a list of the 36
 adjectives (for example, "fatigued") and were asked to rate
 
them in the standard fashion on a scale ranging from 0 (not
 at all) to 4 (extremely) 
according to how they had been feeling
 during the past week. Factor analysis of 
the results in the
 present study (data not shown) revealed a questionnaire structure
 closely similar to that reported for the full scale in the manual.
18 The scores for 
each set of related adjectives were added together
 to produce the subscale scores, 
and a summary total score for
 each patient was calculated by adding the results for 
the first
 five subscales and subtracting the last subscale (that is, vigour/activity).
  
STATISTICAL ANALYSIS
  
The principal assessment of the effects of the treatment to
 lower cholesterol 
concentration on mood was based prospectively
 on the comparison of the results 
of patients allocated to either
 of the two simvastatin groups (as both doses had 
been shown
 to produce similar large reductions in cholesterol concentration
17)
 
versus the placebo group. A subsidiary assessment entailed comparisons
 of 40 mg 
simvastatin daily versus 20 mg simvastatin. All comparisons
 were made by 
allocated treatment group among patients completing
 the questionnaire 
irrespective of compliance (that is, "intention
 to treat" except that non-survivors 
and some other patients
 did not complete the questionnaire; see below). 
2 Tests 
for
 heterogeneity and trend were used to compare the proportion
 of patients with 
different mood scores between the treatment
 groups. As these data tended to be 
skewed, medians with upper
 and lower quartiles are given. Use of psychotropic 
medication
 after randomisation was used as another index of psychological
 
disturbance. Two sided P values are used throughout, and differences
 are 
described as non-significant if 2P >0.05. The study had
 good power to detect a 
shift in the distribution of the total
 score of the profile of mood questionnaire 
among patients in
 the combined simvastatin group, such that at least two thirds
 
(rather than half) had scores above the median score of the
 placebo control group.
  
Results
  
PATIENT CHARACTERISTICS
  
At the time of administration of the questionnaire 49 of the
 original sample of 621 
patients had died and nine were not being
 followed up in the clinic or by 
telephone. Completed questionnaires
 were obtained from 491 (87%) of the 563 
survivors offered the
 questionnaire. The proportions completing the mood 
questionnaires
 were similar in each treatment group (166 allocated to 40 mg
 
simvastatin, 168 to 20 mg simvastatin, and 157 to placebo).
 Baseline 
characteristics of the 491 patients who completed the
 questionnaire (table 1) were 
similar to those of the 621 originally
 randomised.
17 Non-completers, however, 
were more likely to be
 smokers (22% v 12%) and to have a history of myocardial 
infarction
 (72% v 59%) and less likely to be married (76% v 86%). The average
 
blood cholesterol concentration at screening was 7.0 mmol/l,
 the average age was 
63.5 years, and 84% of the patients were
 men. All characteristics recorded were 
well balanced between
 groups at randomisation, although slightly more of those 
allocated
 to simvastatin were already taking psychotropic medication.
  
 
 
 Table 1--Baseline characteristics of all randomised patients. 
Figures are numbers 
(percentages) of subjects unless stated otherwise 
-------------------------------------------------------------
---------------------------- 
                                    Patients completing mood     
Patients not completing 
                                           questionnaire           
mood questionnaire 
-------------------------------------------------------------
---------------------------- 
                                    Simvastatin                 
Simvastatin 
                                     20 mg or       Placebo      
20 mg or     Placebo 
                                      40 mg         control       
40 mg       control 
Detail                               (n = 334)      (n = 157)    
(n = 80)     (n = 50) 
-------------------------------------------------------------
---------------------------- 
Mean age (years)                       63.3           63.8        
63.7         63.6 
Mean total cholesterol (mmol/l)         7.0            6.9         
7.1          7.2 
Mean calculated low density 
 lipoprotein cholesterol (mmol/l)       4.8            4.7         
4.8          4.7 
Mean high density lipoprotein 
 cholesterol (mmol/l)                  1.17           1.14        
1.14         1.21 
Mean triglycerides (mmol/l)            2.52           2.59        
2.69         2.77 
Men                                  282 (84)       132 (84)     
70 (88)      42 (84) 
Current smokers                       44 (13)        16 (10)     
14 (18)      14 (28) 
Prior myocardial infarction          195 (58)        95 (61)     
60 (75)      33 (66) 
Prior cerebrovascular accident        30 (9)         17 (11)      
7 (9)        3 (6) 
Prior peripheral vascular disease     32 (10)        14 (9)       
9 (11)       7 (14) 
Treated diabetes                      11 (3)          6 (4)       
2 (3)        1 (2) 
Married                              286 (86)       137 (87)     
64 (80)      35 (70) 
Any psychotropic drugs before entry: 
  Minor tranquillisers                16 (5)          6 (4)       
9 (11)       4 (8) 
  Major tranquillisers                 4 (1)          0           
0            0 
  Prochlorperazine                     3 (1)          0           
3 (4)        0 
  Antidepressants                     12 (4)          6 (4)       
5 (6)        1 (2) 
  Lithium                              0              0           
0            0 Compliance with study treatment (defined as more than 90% of
 scheduled tablets 
being taken) was good, and the numbers who
 had stopped study treatment were 
evenly balanced between the
 treatment groups (26 of those allocated 40 mg 
simvastatin versus
 19 allocated 20 mg simvastatin versus 20 allocated placebo).
 
Changes in lipids were similar to those in the study as a whole
17 with mean (SE) 
total cholesterol concentration reduced at the
 time of the questionnaire by 2.0 (0.1) 
mmol/l (28.3 (1.9)% reduction)
 among those allocated 40 mg daily simvastatin 
and by 1.8 (0.1)
 mmol/l (25.3 (1.6)% reduction) among those allocated 20 mg 
daily
 simvastatin compared with 0.1 (0.1) mmol/l (1.0 (1.5)% reduction)
 in the 
placebo group. Sustained reductions of this magnitude
 (an average of 1.9 mmol/l 
or 26.7% among those allocated simvastatin)
 maintained for nearly three years 
provide a strong basis on
 which to evaluate any possible adverse effects of 
lowering cholesterol
 concentration on mood.
  
ASSESSMENT OF MOOD
  
Table 2 shows the distribution of subscale scores on the profile
 of mood state 
questionnaire and the total mood disturbance scores
 for those patients who 
completed the questionnaire. There were
 no significant differences in the 
distribution of any of these
 scores between the two simvastatin groups combined 
and the placebo
 group. Nor were there any differences in the subsidiary 
comparison
 between those allocated 40 mg daily simvastatin and those allocated
 
20 mg daily simvastatin (data not shown). To evaluate the possibility
 that only 
people with lower baseline cholesterol concentrations
 would be susceptible to any 
adverse effects on mood of a reduction
 in concentration, the results for the 258 
patients with baseline
 concentrations below the mean of 7.0 mmol/l were analysed 
separately.
 We found no significant differences between subjects allocated
 to 
simvastatin or placebo (table 3). Nor were there significant
 differences between 
the treatment groups among men and women
 analysed separately nor among 
patients aged 70 years or above,
 whom, it has been suggested,
6 might be more 
susceptible to any
 effects on mood of lowering cholesterol concentration.
  
 
 
 
Table 2--Distribution of scores on profile of mood state for 
patients completing questionnaire* 
-------------------------------------------------------------
-------------------------------------------------------------
---------------------------- 
                                                                                                               
Any simvastatin v placebo 
                                                      Profile 
of mood state score                                        (
2 tests) 
-------------------------------------------------------------
-------------------------------------------------------------
---------------------------- 
Subscale and                                                                                                
Median                      Linear treatment                  0     1 to 4     5 to 8     9 to 
12     13 to 16     17 to 20     21 to 24      (quartiles)   
Heterogeneity   trend 
-------------------------------------------------------------
-------------------------------------------------------------
---------------------------- 
Tension/anxiety: 
  Simvastatin             2%      46%        32%        12%          
5%           2%           1%         5.0 (3.0,8.0)      3.57        
0.07 
  Placebo                 3%      40%        34%        16%          
5%           1%           0%         5.0 (3.0,8.0) 
Anger/hostility: 
  Simvastatin            24%      46%        22%         6%          
2%           1%           0%         3.0 (1.0,5.0)      3.60        
0.01 
  Placebo                23%      49%        17%        10%          
1%           1%           0%         3.0 (1.0,5.0) 
Fatigue/inertia: 
  Simvastatin             7%      29%        29%        17%         
12%           3%           2%         6.0 (3.0,10.0)    10.28         
0 
  Placebo                 5%      28%        36%        18%          
5%           7%           2%         6.0 (3.0,10.0) 
Confusion/bewilderment: 
  Simvastatin             5%      54%        29%         7%          
4%           0%           0%         4.0 (2.0,6.0)     5.49         
0.11 
  Placebo                 3%      55%        30%         9%          
2%           1%           0%         4.0 (2.0,6.0) 
Depression/dejection: 
  Simvastatin            43%      41%        12%         2%   
0%           1%           0%         1.0 (0.0,3.0)     1.14         
0.15 
  Placebo                43%      43%        11%         1%          
1%           1%           0%         1.0 (0.0,3.0) 
Vigour/activity: 
  Simvastatin             1%       7%        20%        35%         
24%          11%           2%        11.0 (8.0,14.0)    7.43         
0.17 
  Placebo                 2%       6%        23%        28%         
32%           7%           1%        11.0 (8.0,14.0) 
Total score:          -24 to -1     0      1 to 24   25 to 48     
49 to 72     73 to 96     97 to 120 
  Simvastatin            25%       2%        53%        16%          
3%           1%           0%         8.0 (-0.5,22.5)   1.66         
0.08 
  Placebo                25%       4%        52%        15%          
4%           1%           0%         9.5 (-1.0,20.0) 
-------------------------------------------------------------
-------------------------------------------------------------
---------------------------- 
*POMS questionnaires were completed by 334 patients allocated 
simvastatin and 157 allocated placebo. 
All 
2 tests were non-significant. 
 
  
Table 3--Medians (quartiles) of profile of mood state total 
score 
subdivided by baseline characteristics 
-------------------------------------------------------------
--------- 
                                       Total score* 
-------------------------------------------------------------
--------- 
                                Simvastatin 
                                 20 mg or               
Placebo 
Characteristic                    40 mg                 
control 
-------------------------------------------------------------
--------- 
Baseline cholesterol (mmol/l): 
  < 7.0 (mean 6.1)+             9.0 (0.0,24.0)        8.5 (-
2.0,23.0) 
  >/= 7.0 (mean 8.0)+           7.0 (-2.0,20.0)      10.0 
(1.0,20.0) 
Sex: 
  Male                          8.5 (-1.0,23.0)       9.0 (-
1.0,20.0) 
  Female                        5.0 (0.0,22.0)       10.0 
(5.0,25.0) 
Age at randomisation (years): 
  <70                           8.0 (-1.0,22.0)       9.0 
(0.0,20.0) 
  >/=70                        10.0 (1.0,23.0)       12.5 (-
6.0,20.0) 
-------------------------------------------------------------
--------- 
*No significant differences between treatment groups in any 
of these 
subgroups. 
+Mean (SE) reduction in cholesterol concentration with 
simvastatin 
was 1.5 (0.1) mmol/l for those with a mean baseline 
concentration of 
6.1 mmol/l and 2.4 (SE 0.2) mmol/l for those with a mean 
baseline 
concentration of 8.0 mmol/l. 
By the time of the administration of the questionnaire patients
 had been followed 
up an average of 10 times since randomisation.
 The proportions of patients 
completing the questionnaire who
 had reported any symptoms that might possibly 
be related to
 mood were evenly balanced between the treatment groups (table
 4), 
as were the proportions who had stopped study treatment
 for any reason. Adverse 
effects on mood were also evaluated
 by comparison of the proportions of patients 
in each treatment
 group who reported the use of psychotropic medication after
 
randomisation. Neither among patients completing the mood questionnaire
 nor 
among all randomised patients were there significant differences
 between the 
simvastatin and placebo groups, either in the proportions
 of patients using 
psychotropic drugs at any time after randomisation
 (despite a non-significant 
chance excess of use before randomisation
 in the simvastatin groups) or in the differences
 between the treatment groups observed in any of these outcome
 
measures with continued follow up to November 1995--that is,
 an average of six 
years after randomisation.)
  
 
 
 
Table 4--Any reports of symptoms possibly related to mood or 
use of psychotropic drugs at clinic visits up 
to 31 October 1992. Figures are numbers (percentages) of 
subjects 
-------------------------------------------------------------
------------------------------------------------- 
                                       Patients completing                 
Patients not completing 
                                       mood questionnaire                   
mood questionnaire 
-------------------------------------------------------------
------------------------------------------------- 
                                      Simvastatin         
Placebo          Simvastatin          Placebo 
                                       20 mg or            
control          20 mg or            control 
Reported event                      40 mg (n = 334)       (n 
= 157)       40 mg (n = 80)        (n = 50) 
-------------------------------------------------------------
------------------------------------------------- 
Insomnia*:                             165 (49)            84 
(54)           37 (46)             28 (56) 
  Difficulty getting to sleep           16 (5)              7 
(4)             2 (3)               1 (2) 
  Disturbed sleep                       16 (5)             10 
(6)             3 (4)               5 (10) 
  Early waking                          18 (5)              6 
(4)             2 (3)               0 
Fatigue*                               194 (58)            91 
(58)           41 (51)             33 (66) 
Depression                              18 (5)              6 
(4)             5 (6)               5 (10) 
Irritability                             5 (1)              1 
(1)             0                   0 
Personality change                       2 (1)              0                 
0                   0 
Stopped study treatment and 
  main reason:                          47 (14)            20 
(13)           32 (40)             16 (32) 
  Fatigue                                3 (1)              0 
0                   0 
  Personality change                     2 (1)              0                 
0                   0 
  Any other reason                      42 (13)            20 
(13)           32 (40)             16 (32) 
Psychotropic drugs+: 
  Started before randomisation          19 (6)              6 
(4)             8 (10)              1 (2) 
  Started after randomisation           11 (3)              4 
(3)             3 (4)               1 (2)   Any use after randomisation           30 (9)             10 
(6)            11 (14)              2 (4) 
-------------------------------------------------------------
------------------------------------------------- 
*Routinely sought symptoms. 
+Includes major tranquillisers, prochlorperazine, 
antidepressants, and lithium; excludes minor tranquillisers. 
Discussion
  
The data for these analyses were obtained by taking the opportunity
 provided by 
an ongoing randomised placebo controlled trial of
 a drug treatment that produces 
substantial and sustained reductions
 in plasma cholesterol concentrations.
17 A 
comparison of mood
 scores derived from a shortened version of the profile of 
mood
 state questionnaire allowed us to evaluate the possibility that
 lowering 
cholesterol concentration is associated with adverse
 effects on mood.
5 
6 
7 
8 There 
was a high response rate to the
 mood questionnaire (87%) and, although 
completers differed from
 non-completers on certain baseline characteristics, there 
was
 no difference in response rate between the simvastatin and placebo
 groups and 
therefore no reason to suspect any bias in the results.
 In this study, there was no 
evidence after nearly three years
 that the substantial reduction in cholesterol 
concentration
 produced by simvastatin was associated with any adverse mood
 
effects. Nor was there any evidence of adverse effects on patients
 whose baseline 
cholesterol concentration was lower than average
 and so would have been reduced 
to lower absolute concentrations.
 There was a slightly, though non-significantly, 
higher use of
 psychotropic drugs in the simvastatin group before randomisation
 
and the start of study treatment but no evidence for differences
 between groups in 
new use of psychotropic drugs during the treatment
 period (up to more than five 
years after randomisation).
  
The selection procedures for this trial should be considered
 in the interpretation 
and generalisation of the results. Patients
 entered in this study had to have 
cardiovascular disease and
 to be free from psychiatric conditions which might 
compromise
 compliance. Moreover, only those who were successfully compliant
 
in the placebo "run in" period before randomisation were included
 in the trial. This 
may have produced a group with a combination
 of cardiovascular disease and 
unusually good psychological health
 in whom vulnerability to any adverse effects 
of a reduction
 in cholesterol concentration might be different from that of
 other 
populations. In view of the fact that long term compliance
 is required for clinical 
use of cholesterol lowering drugs,
 however, these results are directly relevant to 
other patients
 who comply with a pharmacological regimen.
  
Overall, these results give little support to the idea that
 reducing cholesterol 
concentration has adverse effects on mood
 in a psychologically healthy sample. 
The patients treated with
 simvastatin, who had experienced a substantial and 
prolonged
 reduction in concentration, were no more depressed, anxious,
 hostile, or 
confused and no more likely to start psychotropic
 medication than those who had 
been on placebo and had had a
 minimal reduction in cholesterol concentration.
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